AstraZeneca Healthcare Policy Research VP James Cai On Building A CRO Community In China: An Interview With PharmAsia News
This article was originally published in The Pink Sheet Daily
Executive Summary
Cai talks about the growing CRO landscape in China and how multinational companies can work with local CROs to improve the clinical trial infrastructure.
You may also be interested in...
China Will Issue New Fast-Track Procedure For Drug Registration – CDE Official
SHANGHAI - China's State FDA will launch a new fast-track mechanism by year end called the special approval procedure for drug registration to accelerate drug registration, SFDA Center for Drug Evaluation Official Yi Feng, told China Trials 2008 attendees here Nov. 10
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.